EMMPRIN: A potential biomarker for predicting the presence of obstructive sleep apnea

Abstract

BackgroundObstructive Sleep Apnea (OSA) is a sleep-related breathing disorder which is strongly associated with the development of cardiovascular diseases. The aim of the study was to investigate the association between circulating extracellular matrix metalloproteinase inducer (EMMPRIN) and OSA risk. MethodsThis was a cross-sectional study in which a total of 144 patients were recruited. Demographic data, blood biochemical parameters and polysomnography parameters were collected. We used a powerful high-throughput Multiplex Immunobead Assay technique to simultaneously detect circulating levels of EMMPRIN and E-selectin. ResultsCirculating levels of EMMPRIN were significantly increased in patients with OSA compared to controls (7.58[6.21–8.80] vs 1.47[0.80–5.91] ng/ml, P < 0.001). After adjusting for confounding factors, we found that circulating EMMPRIN levels were independently associated with the presence of OSA (odds ratio[OR] = 2.240, 95% confidence interval [CI] = 1.391–3.607, P < 0.001). Furthermore, circulating EMMPRIN showed greater discriminatory accuracy in predicting the presence of OSA (AUC:0.904). ConclusionsCirculating EMMPRIN levels were significantly increased in patients with OSA, and may be a novel marker for predicting the risk of OSA.